In conclusion, we demonstrate that molecular biology for BCR::ABL1 quantification and ABL1 mutation screening represents an essential and necessary approach for CML treatment follow-up and therapy adaptation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.